NCT02974647 2026-04-22
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Incyte Corporation
Federal Research Institute of Pediatric Hematology, Oncology and Immunology